Actively Recruiting
Gangwon PCI Prospective Registry
Led by Yonsei University · Updated on 2024-07-24
5000
Participants Needed
3
Research Sites
991 weeks
Total Duration
On this page
Sponsors
Y
Yonsei University
Lead Sponsor
G
Gangwon Cardiovascular Health Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Comparison of * Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore * Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott, USA * Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent Medtronic, USA in patients with coronary artery disease treated with percutaneous coronary intervention
CONDITIONS
Official Title
Gangwon PCI Prospective Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 19 years
- Able to verbally confirm understanding of risks, benefits, and alternatives of receiving drug-eluting stents
- Provides written informed consent before any study procedures
- Has significant stenosis (greater than 50%) in a native or in-stent coronary artery
- Has evidence of myocardial ischemia such as stable or unstable angina, recent or acute myocardial infarction, positive functional studies, or reversible ECG changes
- For stenosis greater than 75%, evidence of myocardial ischemia is not required
You will not qualify if you...
- Known allergy or contraindication to heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9, everolimus, zotarolimus, stainless steel, cobalt chromium, or contrast media (except those with manageable contrast sensitivity)
- Use of systemic biolimus A9, everolimus, or zotarolimus within the past 12 months
- Female of childbearing potential who is pregnant or plans to become pregnant without a recent negative pregnancy test
- Planned elective surgery requiring stopping antiplatelet therapy within 12 months after enrollment
- Non-cardiac conditions with life expectancy less than 2 years or likely protocol non-compliance
- Cardiogenic shock at presentation
- Currently participating in another investigational drug or device study without completing primary endpoint follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Chuncheon Hallym University Hospital
Chuncheon, Gangwon-do, South Korea
Not Yet Recruiting
2
Yonsei University Wonju Christian Hospital
Wŏnju, Gangwon-do, South Korea, 220768
Actively Recruiting
3
Korea University Guro Hospital
Seoul, South Korea
Actively Recruiting
Research Team
J
Junghan Yoon, M.D., Ph.D.
CONTACT
Y
Young Jin Youn, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here